Targeting memory loss with aspirin, a molecular mechanism perspective for future therapeutic approaches

Inflammopharmacology. 2023 Dec;31(6):2827-2842. doi: 10.1007/s10787-023-01347-1. Epub 2023 Nov 4.

Abstract

Acetylsalicylic acid (ASA), also known as aspirin, was discovered in 1897 as an acetylated form of salicylate. It has been widely used for its anti-inflammatory and antiplatelet effects. It is commonly used for its cardiovascular benefits and is prescribed as secondary prophylaxis after a heart attack. Furthermore, low-dose, long-term ASA is used to reduce the risk of heart attack and stroke in individuals without prior cardiovascular disease. Acetylsalicylic acid acts as a non-selective inhibitor of cyclooxygenase (COX), which inhibits the synthesis of prostaglandins and prevents pro-inflammatory cytokines. Findings suggest that targeting cytokines and growth factors could be a potential therapeutic strategy for reducing neuroinflammation and slowing down the progression of dementia. Additionally, prostaglandins contribute to synaptic plasticity and can act as retrograde messengers in synapses. Research has implicated COX-1, one of the isoforms of the enzyme, in neuroinflammation and neurodegenerative disorders. The inhibition of COX-1 might potentially prevent impairments in working memory and reduce neuroinflammation caused by beta-amyloid proteins in some conditions, such as Alzheimer's disease (AD). Cyclooxygenase-2, an inducible form of the enzyme, is expressed in cortical and hippocampal neurons and is associated with long-term synaptic plasticity. The inhibition or knockout of COX-2 has been shown to decrease long-term potentiation, a process involved in memory formation. Studies have also demonstrated that the administration of COX-2 inhibitors impairs cognitive function and memory acquisition and recall in animal models. There remains a debate regarding the effects of aspirin on dementia and cognitive decline. Although some studies suggest a possible protective effect of non-steroidal anti-inflammatory drugs, including aspirin, against the development of AD, others have shown inconsistent evidence. This review provides an overview of the effects of ASA or its active metabolite salicylate on learning, memory, and synaptic plasticity.

Keywords: Acetylsalicylic acid; Alzheimer; Cyclooxygenase; Dementia; Synaptic plasticity.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Alzheimer Disease* / prevention & control
  • Animals
  • Anti-Inflammatory Agents / therapeutic use
  • Aspirin / pharmacology
  • Aspirin / therapeutic use
  • Cyclooxygenase 2 / metabolism
  • Cytokines
  • Humans
  • Memory Disorders / drug therapy
  • Myocardial Infarction* / drug therapy
  • Neuroinflammatory Diseases
  • Prostaglandins

Substances

  • Aspirin
  • Anti-Inflammatory Agents
  • Prostaglandins
  • Cyclooxygenase 2
  • Cytokines